血清核苷酸还原酶亚单位 M2 在慢性肝病和肝细胞癌患者中的变化。

Serum Ribonucleotide Reductase Subunit M2 in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma.

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital.

Department of Geriatrics, School of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.

出版信息

Lab Med. 2023 Nov 2;54(6):626-632. doi: 10.1093/labmed/lmad013.

DOI:10.1093/labmed/lmad013

PMID:36944169

Abstract

BACKGROUND

Ribonucleotide reductase subunit M2 (RRM2) plays a key role in cell and hepatitis B virus (HBV) replication. Nevertheless, its clinical implications for managing liver diseases have been inadequately studied.

METHODS

A total of 412 participants were enrolled, including 60 healthy control individuals, 55 patients with chronic hepatitis B (CHB), 173 patients with cirrhosis, and 124 patients with hepatocellular carcinoma (HCC). Serum RRM2 was measured via ELISA.

RESULTS

The level of serum RRM2 in patients with CHB, cirrhosis, and HCC was higher than that in healthy controls (P < .05). A large difference in serum RRM2 was found between HBV-related and non-HBV-related patients in the cirrhosis group (P < .001), compared with the difference between HBV-related HCC and non-HBV-related HCC (P = .86). In the HBV-related cirrhosis group, the serum RRM2 level showed significant positive correlations with HBV DNA, hepatitis B surface antigen, hepatitis B e antigen, Child-Pugh scores, and MELD scores and played a strong role in diagnosing HBV-related cirrhosis in CHB, compared with fibrosis-4 score and aspartate aminotransferase-to-platelet ratio index.

CONCLUSIONS

Serum RRM2 is a reliable biomarker for accurate HBV-related cirrhosis diagnosis and evaluation. Also, serum RRM2 could reflect the expression state of HBV replication in patients with HBV-related cirrhosis.

摘要

背景

核糖核苷酸还原酶亚单位 M2（RRM2）在细胞和乙型肝炎病毒（HBV）复制中发挥关键作用。然而，其在管理肝脏疾病方面的临床意义尚未得到充分研究。

方法

共纳入 412 名参与者，包括 60 名健康对照者、55 名慢性乙型肝炎（CHB）患者、173 名肝硬化患者和 124 名肝细胞癌（HCC）患者。通过 ELISA 测量血清 RRM2。

结果

CHB、肝硬化和 HCC 患者的血清 RRM2 水平高于健康对照组（P <.05）。肝硬化组中，HBV 相关和非 HBV 相关患者之间的血清 RRM2 水平存在较大差异（P <.001），而 HBV 相关 HCC 与非 HBV 相关 HCC 之间的差异较小（P =.86）。在 HBV 相关肝硬化组中，血清 RRM2 水平与 HBV DNA、乙型肝炎表面抗原、乙型肝炎 e 抗原、Child-Pugh 评分和 MELD 评分呈显著正相关，在诊断 CHB 中的 HBV 相关肝硬化方面，其作用强于纤维化-4 评分和天冬氨酸氨基转移酶-血小板比值指数。